parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in microglia (698 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 321	0.91
pathways Reactome	3 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 5733

SPRED1 in dopamine neurons, braak+0.41 (p 0.273) → +0.13 (p 0.739)receipt 5740
SPRED1 in microglia, braak+0.55 (p 0.128) → -0.12 (p 0.767)receipt 5739

receipt 5740: SPRED1 in dopamine neurons, braak

power: full sample +0.24 (p 0.332, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.23 (p 0.355, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.25 (p 0.315, n 18). could be the mix.
skeptic: leave-one-out range +0.17 to +0.43, sign flips 0; without severely affected donors +0.24 (p 0.332, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SPRED1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5739: SPRED1 in microglia, braak

power: full sample +0.21 (p 0.413, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.13 (p 0.597, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.16 (p 0.538, n 18). could be the mix.
skeptic: leave-one-out range +0.10 to +0.31, sign flips 0; without severely affected donors +0.21 (p 0.413, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SPRED1 in microglia.

case closed: nothing better to follow up.

loading the receipts